List of Epsolay drug patents

Epsolay is owned by Galderma Labs Lp.

Epsolay contains Benzoyl Peroxide.

Epsolay has a total of 6 drug patents out of which 0 drug patents have expired.

Epsolay was authorised for market use on 22 April, 2022.

Epsolay is available in cream;topical dosage forms.

Epsolay can be used as topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older, topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older.

The generics of Epsolay are possible to be released after 18 August, 2040.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9868103 GALDERMA LABS LP Metal oxide coating of water insoluble ingredients
Aug, 2028

(5 years from now)

US9687465 GALDERMA LABS LP Compositions for the treatment of rosacea
Nov, 2032

(9 years from now)

US10945987 GALDERMA LABS LP Method for providing early onset of action in the treatment of rosacea
Feb, 2040

(16 years from now)

US10933046 GALDERMA LABS LP Method for treatment of rosacea in patients aged 65 years and older
Feb, 2040

(16 years from now)

US11541026 GALDERMA LABS LP Method for treatment of rosacea
Feb, 2040

(16 years from now)

US11426378 GALDERMA LABS LP Method for long-term treatment of rosacea
Aug, 2040

(17 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 22, 2025

Drugs and Companies using BENZOYL PEROXIDE ingredient

Market Authorisation Date: 22 April, 2022

Treatment: Topical treatment of inflammatory lesions of rosacea in adults 18 years of age and older; Topical treatment of inflammatory lesions of rosacea in adults 65 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage

EPSOLAY family patents

29

United States

7

IB

5

Canada

3

European Union

2

Israel

1

Korea, Republic of

1

Japan

1

Australia

1

EA

1

South Africa

1

China

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic